Elevate your local knowledge
Sign up for the iNFOnews newsletter today!
VANCOUVER – Cardiome Pharma Corp. (TSX:COM) said Wednesday that Merck is returning the global marketing and development rights for both the intravenous and oral formulations for vernakalant.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Want to share your thoughts, add context, or connect with others in your community?
You must be logged in to post a comment.